Results 71 to 80 of about 1,734 (194)

Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance [PDF]

The Journal of Infectious Diseases, 2007
The cytomegalovirus (CMV) UL97 kinase inhibitor maribavir (MBV) is undergoing clinical antiviral trials. Two clinical CMV isolates serially passaged in cell culture under MBV showed >20-fold increases in MBV resistance after the development of the UL97 mutation V353A in one of the isolates and of T409M in the other.
Sunwen, Chou, Laura C Van, Wechel, Gail I, Marousek   +2 more
openaire   +2 more sources

Análisis descriptivo de los planes de investigación en pediatría resueltos por la Agencia Europea del Medicamento durante el periodo 2007-2009 [PDF]

, 2011
Análisis descriptivo de la información contenida en los Planes de Investigación Pediátricos (PIPs) resueltos por la Agencia Europea del Medicamento durante los años 2007-2009, para analizar tanto las características de los medicamentos que han presentado
Ferrando Noguera, Vicenta, Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona. Facultat de Medicina   +2 more
core   +1 more source

Effect of antivirals on clinical and lab-adapted human cytomegalovirus strains using induced pluripotent stem cell-derived human neural models [PDF]

Human cytomegalovirus (CMV) infections can cause severe neurological complications, particularly in newborns and immunocompromised patients. Children affected with congenital CMV infection may develop long-term neurological damage and intellectual ...
Calitz, Carlemi, Cornelissen, Marion, Freeze, Eline, Kampen, Jeroen Van, Koen, Gerrit, Korsten, Joep, Molenkamp, Richard, Mulder, Lance A., Pajkrt, Dasja, Schotting, Amber J., Sridhar, Adithya, Vieira da Sá, Renata, Wolthers, Katja C., Zorgdrager, Fokla   +13 more
core   +1 more source

Discovery of a Baloxavir‐Inspired Endonuclease Inhibitor That Prevents Herpes Simplex Virus 1 Replication in Cell Culture and In Vivo

Advanced Science, Volume 12, Issue 42, November 13, 2025.
Current herpesvirus treatments targeting the viral DNA polymerase are limited by toxicities and drug resistance. Novel compounds inhibiting the nuclease activity of the herpes simplex virus 1 (HSV‐1) terminase complex, required for viral genome packaging, have been identified.
Sabina Andreu, Kai Tang, Jiahui Zhou, Gabriel Pino‐Peco, Nerea López‐Carrobles, Raquel Bello‐Morales, Daniel Galdo‐Torres, Lina Zhang, Federico Gago, José Antonio López‐Guerrero, Xinyong Liu, Peng Zhan, Luis Menéndez‐Arias   +12 more
wiley   +1 more source

State‐of‐the‐Art on Model‐Informed Drug Development Approaches for Pediatric Rare Diseases

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 11, Page 1743-1759, November 2025.
ABSTRACT Pediatric rare diseases present unique challenges for drug development due to small patient populations, ethical constraints on clinical trial design, and limited prospectively defined natural history data. Model‐Informed Drug Development (MIDD) has emerged as a powerful paradigm to address these challenges by leveraging quantitative methods ...
Rajesh Krishna, Amitava Mitra, Matthew L. Zierhut, Lilly East, Chandra Durairaj   +4 more
wiley   +1 more source

Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir

Virology Journal, 2009
The UL97 kinase has been shown to phosphorylate and inactivate the retinoblastoma protein (Rb) and has three consensus Rb-binding motifs that might contribute to this activity.
Chou Sunwen, Hartline Caroll B, Frederick Samuel L, Gill Rachel B, Prichard Mark N   +4 more
doaj   +1 more source

Current Progress in Targeting Human Cytomegalovirus Infection

iLABMED, Volume 3, Issue 3, Page 303-311, September 2025.
This review highlights recent advances in the mechanisms by which human cytomegalovirus (HCMV) maintains its genome in infected cells, as well as the cellular factors and viral antigens that modulate viral reactivation, which reveal potential targets for addressing HCMV infection.
Yonggang Pei, Jun Chen
wiley   +1 more source

The Cytomegalovirus Protein Kinase pUL97: Host Interactions, Regulatory Mechanisms and Antiviral Drug Targeting

Microorganisms, 2020
Human cytomegalovirus (HCMV) expresses a variety of viral regulatory proteins that undergo close interaction with host factors including viral-cellular multiprotein complexes.
Mirjam Steingruber, Manfred Marschall
doaj   +1 more source

Prognostic Impact of Cytomegalovirus Reactivation After Transplantation From Cord Blood Compared to Other Donor Sources in Patients With Adult T‐Cell Leukemia/Lymphoma in the Pre‐Letermovir Era

Transplant Infectious Disease, Volume 27, Issue 5, September/October 2025.
Cytomegalovirus reactivation (CMV‐react) is an indicator to predict the increased non‐relapse mortality and decreased overall survival in adult T‐cell leukemia‐lymphoma patients who received allogeneic transplantation from HLA‐matched related and unrelated donors.
Takuya Fukushima, Hidehiro Itonaga, Hikaru Sakamoto, Wataru Takeda, Masahito Tokunaga, Takeharu Kato, Takuro Kuriyama, Toshiro Kawakita, Machiko Fujioka, Yasuhiko Miyazaki, Naoyuki Uchida, Yasuo Mori, Hirohisa Nakamae, Masao Ogata, Kazunori Imada, Makoto Onizuka, Kazuho Morichika, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Shigeo Fuji, Makoto Yoshimitsu, ATL Working Group of the Japanese Society for Transplantation and Cellular Therapy   +22 more
wiley   +1 more source

Real-World Comparison of Maribavir to Foscarnet for the Treatment of Cytomegalovirus in Solid Organ and Hematopoietic Stem Cell Transplant Recipients

Viruses
Cytomegalovirus (CMV) infection in solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients may increase the risk of rejection or allograft dysfunction, other infection(s), and morbidity and mortality.
Lauren Ogawa, Chelsea Morinishi, Ashrit Multani, Pryce Gaynor, Omer E. Beaird, Christine Pham, Joanna M. Schaenman   +6 more
doaj   +1 more source